ALIMP — Implanet SA Share News
0.000.00%
Last trade - 00:00- €21.42m
- €25.87m
- €12.47m
Brief: Implanet launches new JAZZ Claw implant
Brief: Implanet Q1 revenue rises 24% to 2.0 million euros
Brief: Implanet commences trading on OTCQX in the U.S.
Brief: Implanet receives green light to market JAZZ Lock implant
Brief: Implanet FY net loss widens to 8.0 million euros
Brief: Implanet FY total revenue falls to 6.7 million euros
Brief: Implanet admitted to Euronext Paris, on "long-seulement" segment
Brief: Implanet granted ANVISA regulatory approval in Brazil to market the JAZZ Band platform
Brief: Implanet Q3 revenue up at 1.7 million euros
Brief: Implanet launches max 5 mln euros convertible bonds issue
Brief: New JAZZ Band FDA clearance expands posterior fixation
Brief: Implanet H1 net loss widens to 4.3 mln euros
Brief: Implanet Q2 revenue decreases at 1.7 million euro
Brief: Implanet enrolls first patient in major multi-center clinical study
Brief: Implanet gets CE mark and FDA clearance for new JAZZ diameters
Brief: Implanet Q1 revenue falls to 1.6 million euros
Brief: Implanet announces results of study of Jazz Implant
Brief: Implanet FY 2014 revenue of 6.3 million euros, up 28 pct yoy
Brief: Implanet publishes cost efectiveness study of JAZZ